Pathogenesys performs mutational analysis for the identification of specific gene aberration in the conduct of clinical trials. Certain genetic mutations have been shown to be predictive of response to certain drugs. The utility of these tests is currently being investigated.

Our approach involves:

• -Isolation of DNA from paraffin sections
• -Introduction of novel restriction enzyme sites in the target gene using first round PCR
• -Nested or Semi-nested PCR followed by enzymatic restriction to identify the presence of mutations
• -Enrichment of mutational sequences using the enzymatic restriction to eliminate wild type
• -Sequencing of mutational sequences

We are currently developing mutational analyses for other genetic loci, a region-specific mutational screening methodology that will yield sequencable DNA products, a novel in situ method for identification of mutant alleles and novel allele-specific PCR approaches for the identification of mutations from tissue or serum DNA. For more details on these approaches, please call Dr. James Thompson at 949-258-0318 or e-mail him at jthompson@pathogenesys.com .

[Home] [About Us] [Mission Statement] [Services] [Clinical Trial Biomarker Algorithms] [Pharama Test Menu] [CLIA Test Menu] [Assay Validation] [Proprietary Technologies] [Investment Opportunities] [FAQ] [News] [References] [Contractual Relationship] [Events] [Study Reporting]